Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence (Q35936247)

11 August 2017

1 reference

title

Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence (English)

1 reference

11 August 2017

Michael E Thase

1

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

808-16, 818-21

1 reference

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Transcranial magnetic stimulation: applications in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Medication resistance and clinical response to electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Treatment-resistant depression: a critique of current approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Definition and epidemiology of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Buspirone augmentation of antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

When should a trial of fluoxetine for major depression be declared failed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Bupropion and sertraline combination treatment in refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Novel uses of thyroid hormones in patients with affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Thyroid hormone treatment of primary unipolar depression: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Refractory depression: the addition of lithium to fluoxetine or desipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Combining Antidepressants for Treatment-Resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A prospective trial of modafinil as an adjunctive treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Transcranial magnetic stimulation in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Sustained response to open-label venlafaxine in drug-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Depression, IV: STAR*D treatment trial for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Advances in the pharmacologic treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

Resistance to antidepressant medications and short-term clinical response to ECT

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Prevention of relapse in residual depression by cognitive therapy: a controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Pindolol Augmentation of Treatment-Resistant Depressed Patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Combining antidepressants for treatment-resistant depression: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Nortriptyline for treatment-resistant depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Citalopram and Bupropion-SR

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Modafinil augmentation of antidepressant treatment in depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Prevalence of sexual dysfunction among newer antidepressants.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Evidence of the dual mechanisms of action of venlafaxine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

The effectiveness of switching antidepressants during remission: a case series of depressed patients who experienced intolerable side effects

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Paroxetine/bupropion combination treatment for refractory depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Refractory Depression: Relevance of Psychosocial Factors and Therapies

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

MAOIs in the Contemporary Treatment of Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Venlafaxine and treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Treatment of Major Depression With Psychotherapy or Psychotherapy-Pharmacotherapy Combinations

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

Identification of a claims data "signature" and economic consequences for treatment-resistant depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900002236

7 January 2021

10.1017/S1092852900002236

Identifiers

DOI

1 reference

11 August 2017

1 reference